RBC Analysts Comment On Intuitive Surgical

On Wednesday, analysts at RBC commented on shares of Intuitive Surgical, Inc. ISRG.

Glenn Novarro feels that “in the worst case scenario the company may witness 6%-8% of total procedures exposed to potential decline in useage of laparoscopic powered morcellators after FDA warning and HCA ban.”

Moreover, “Not all of these potential “at risk” procedures expected to move completely away from robotic surgery platform, leaving ISRG with “much lower” risk.”

Lastly, Novarro Sees “limited negative read-through to Hologic, whose Myosure hysteroscopic morcellator doesn’t pose same degree of risk as laparoscopic powered morcellators.”

Shares of Intuitive Surgical recently traded at $512.59, down 0.76 percent.